Northwestern University
Amy Paller
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) the administration of dupilumab will be well-tolerated, regardless of underlying genetic skin disorder. The total clinical study duration will be 26 months (104 Weeks). The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
Skin Diseases
Dupilumab
Early Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 30 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders: a Single-Site Pilot Study |
Actual Study Start Date : | June 12, 2023 |
Estimated Primary Completion Date : | June 30, 2025 |
Estimated Study Completion Date : | June 1, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Open-Label Dupilumab |
Drug: Dupilumab |
Ages Eligible for Study: | 6 Months |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611